Novartis AG
Human mesothelin chimeric antigen receptors and uses thereof

Last updated:

Abstract:

Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor(CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

Status:
Grant
Type:

Utility

Filling date:

19 Dec 2014

Issue date:

5 May 2020